Long noncoding RNA RFPL1S-202 inhibits ovarian cancer progression by downregulating the IFN-β/STAT1 signaling

Liu, Siyu; Chen, Xiyi; Huang, Ke; Xiong, Xueyou; Shi, Yaqian; Wang, Xusu; Pan, Xinxing; Cong, Yu; Sun, Yu; Ge, Lili; Xu, Juan; Jia, Xuemei

doi:10.1016/j.yexcr.2022.113438

Cited by 9 publications

(11 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(II) As transcriptional regulators, lncRNAs can bind to downstream gene promoters ( 36 ), transcription factors ( 37 , 38 ), or recruit complexes to regulate gene expression patterns ( 39 ). (III) At the post-transcriptional level, lncRNAs interact with splicing factors to splice precursor mRNAs ( 40 ), combine with RNA-binding protein and affect mRNA stability ( 41 , 42 ), and bind to proteins or mRNAs and impact their biological functions ( 43 , 44 ). (IV) LncRNA acting as microRNAs (miRNAs) sponges to regulate the expression of their targets ( 45 , 46 ).…”

Section: Overview Of Lncrnamentioning

confidence: 99%

The roles of long non-coding RNAs in ovarian cancer: from functions to therapeutic implications

Hu,

Yuan,

Yang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are multifunctional and participate in a variety of biological processes and gene regulatory networks. The deregulation of lncRNAs has been extensively implicated in diverse human diseases, especially in cancers. Overwhelming evidence demonstrates that lncRNAs are essential to the pathophysiological processes of ovarian cancer (OC), acting as regulators involved in metastasis, cell death, chemoresistance, and tumor immunity. In this review, we illustrate the expanded functions of lncRNAs in the initiation and progression of OC and elaborate on the signaling pathways in which they pitch. Additionally, the potential clinical applications of lncRNAs as biomarkers in the diagnosis and treatment of OC were emphasized, cementing the bridge of communication between clinical practice and basic research.

show abstract

Section: Overview Of Lncrnamentioning

confidence: 99%

The roles of long non-coding RNAs in ovarian cancer: from functions to therapeutic implications

Hu,

Yuan,

Yang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Liu's study revealed that lncRNA RFPL1S‐202 played a significant role in enhancing the apoptotic effects of paclitaxel and cisplatin on OC cells. Mechanistically, RFPL1S‐202 physically interacted with DDX3X/ALKBH5, thereby decreasing the expression of IFN by increasing the m6A modification of IFNB1 125 . In addition, when comparing to primary OC tissues, LINC02489 expression decreased dramatically in metastatic and chemoresistant OC tissues.…”

Section: Interaction Between M6a Modification and Lncrna In Cancer Dr...mentioning

confidence: 99%

New insights into the interaction between m6A modification and lncRNA in cancer drug resistance

Jin,

Fan

2023

Cell Proliferation

View full text Add to dashboard Cite

Drug resistance is perhaps the greatest obstacle in improving outcomes for cancer patients, leading to recurrence, progression and metastasis of various cancers. Exploring the underlying mechanism worth further study. N6‐methyladenosine (m6A) is the most common RNA modification found in eukaryotes, playing a vital role in RNA translation, transportation, stability, degradation, splicing and processing. Long noncoding RNA (lncRNA) refers to a group of transcripts that are longer than 200 nucleotides (nt) and typically lack the ability to code for proteins. LncRNA has been identified to play a significant role in regulating multiple aspects of tumour development and progression, including proliferation, metastasis, metabolism, and resistance to treatment. In recent years, a growing body of evidence has emerged, highlighting the crucial role of the interplay between m6A modification and lncRNA in determining the sensitivity of cancer cells to chemotherapeutic agents. In this review, we focus on the recent advancements in the interaction between m6A modification and lncRNA in the modulation of cancer drug resistance. Additionally, we aim to explore the underlying mechanisms involved in this process. The objective of this review is to provide valuable insights and suggest potential future directions for the reversal of chemoresistance in cancer.

show abstract

“…IFNB1 regulates the Th17 immune response [33], and IL-17A induces the production of IL-8 [43], while CCL2 promotes inflammatory processes in psoriasis [44]. Through the canonical JAK/STAT signaling pathway, the IFNB1-initiated response regulates cell proliferation [45], which is known to be dysregulated in psoriasis. Therefore, the differential expression of H2AFY in Among the replication-independent histones that modulate nucleosome plasticity [12,35], MACROH2A1 (also known as H2AFY), H2AZ1 (also known as H2AFZ), and H3F3A/B show altered expression in uninvolved skin (Figure 1).…”

Section: Histonesmentioning

confidence: 99%

“…IFNB1 regulates the Th17 immune response [33], and IL-17A induces the production of IL-8 [43], while CCL2 promotes inflammatory processes in psoriasis [44]. Through the canonical JAK/STAT signaling pathway, the IFNB1-initiated response regulates cell proliferation [45], which is known to be dysregulated in psoriasis. Therefore, the differential expression of H2AFY in uninvolved psoriatic skin is likely to play a massive role in triggering psoriasis-related dysregulation in innate immune and proliferation-related responses (Figure 2).…”

Section: Histonesmentioning

confidence: 99%

Histone and Histone Acetylation-Related Alterations of Gene Expression in Uninvolved Psoriatic Skin and Their Effects on Cell Proliferation, Differentiation, and Immune Responses

Romhányi,

Szabó,

Kemény

et al. 2023

IJMS

View full text Add to dashboard Cite

Psoriasis is a chronic immune-mediated skin disease in which the symptom-free, uninvolved skin carries alterations in gene expression, serving as a basis for lesion formation. Histones and histone acetylation-related processes are key regulators of gene expression, controlling cell proliferation and immune responses. Dysregulation of these processes is likely to play an important role in the pathogenesis of psoriasis. To gain a complete overview of these potential alterations, we performed a meta-analysis of a psoriatic uninvolved skin dataset containing differentially expressed transcripts from nearly 300 individuals and screened for histones and histone acetylation-related molecules. We identified altered expression of the replication-dependent histones HIST2H2AA3 and HIST2H4A and the replication-independent histones H2AFY, H2AFZ, and H3F3A/B. Eight histone chaperones were also identified. Among the histone acetyltransferases, ELP3 and KAT5 and members of the ATAC, NSL, and SAGA acetyltransferase complexes are affected in uninvolved skin. Histone deacetylation-related alterations were found to affect eight HDACs and members of the NCOR/SMRT, NURD, SIN3, and SHIP HDAC complexes. In this article, we discuss how histone and histone acetylation-related expression changes may affect proliferation and differentiation, as well as innate, macrophage-mediated, and T cell-mediated pro- and anti-inflammatory responses, which are known to play a central role in the development of psoriasis.

show abstract

Long noncoding RNA RFPL1S-202 inhibits ovarian cancer progression by downregulating the IFN-β/STAT1 signaling

Cited by 9 publications

References 42 publications

The roles of long non-coding RNAs in ovarian cancer: from functions to therapeutic implications

The roles of long non-coding RNAs in ovarian cancer: from functions to therapeutic implications

New insights into the interaction between m6A modification and lncRNA in cancer drug resistance

Histone and Histone Acetylation-Related Alterations of Gene Expression in Uninvolved Psoriatic Skin and Their Effects on Cell Proliferation, Differentiation, and Immune Responses

Contact Info

Product

Resources

About